ANTIVIRAL AGENT AGAINST ANIMAL VIRUSES
Disclosed herein is an antiviral agent against animal viruses. The antiviral agent contains a protein or a nucleic acid sequence encoding the protein, as an active ingredient, the protein having binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself. Disclosed herein is further an antiviral animal cell containing the protein according to the present invention, or the nucleic acid sequence encoding the protein. The antiviral agent and antiviral animal cell exhibit advantageous effects in that they selectively degrade foreign nucleic acid chains invaded in an animal cell and have no cytotoxicity to the animal cell, thus causing no death of the animal cell.
The present invention relates to an antiviral agent against animal viruses. More specifically, the present invention relates to an antiviral agent against animal viruses containing, as an active ingredient, a protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself, or a nucleic acid sequence encoding the protein, and an antiviral animal cell containing the protein or the nucleic acid sequence encoding the protein.
BACKGROUND ARTAntiviral agents developed to date are mostly non-protein drugs that exhibit superior antiviral activities such as viral adsorption inhibition, viral penetration inhibition, viral uncoating inhibition, transcription (or translation) inhibition of viral nucleic acid (e.g., viral thymidine kinase inhibition, viral reverse transcriptase inhibition, viral polymerase inhibition, and viral mRNA-capping inhibition) and viral protein synthesis inhibition according to the type of viruses infected and that have relatively low toxicity.
There are several patents associated with antiviral drugs. For example, Korean Patent Application No. 10-2001-0021449, targeting viral transcription inhibition, discloses fusion proteins that inhibit expression of RNA on proviral long terminal repeats (LTRs) in a cell nucleus.
U.S. Pat. No. 5,849,800 discloses an amantadine associated with viral uncoating.
U.S. Pat. No. 4,957,924 discloses an acyclovir as an antiviral drug that inhibits biosynthesis of viral nucleic acid. The acyclovir is a medication prepared by modifying a sugar in nucleic acids and is used to treat herpesvirus infections. The acyclovir competes with deoxyguanosine triphosphate (dGTP) and is incorporated into viral DNA, thus terminating DNA replication.
U.S. Pat. Nos. 5,108,993 and 5,026,687 disclose zidovudine and dideoxyinosine, respectively, reverse transcriptase inhibitors used to treat human immunodeficiency virus (HIV) infections.
U.S. Pat. No. 5,962,725 discloses nelfinavir that suppresses activities of HIV proteases to prevent HIV from producing required proteins.
In addition, arildone and pleconaril are known as antiviral drugs that mediate binding of viruses with host cells, followed by penetration and uncoating. These drugs are reported to inhibit uncoating of capsid proteins from RNA genomes.
Trifluorothymidine is known to be a pyrimidine analogue which is introduced into DNA and thus causes growth of mutants during DNA replication. Foscarnet is known to be bound to herpes DNA polymerase to inhibit DNA replication. Ribavirin and neoplanocin A are known to be guanosine and adenosine analogues that inhibit formation of mRNA cap structures to suppress RNA synthesis.
Other antiviral drugs such as saquinavir, ritonavir and indinavir suppress activities of HIV proteases to prevent HIV from producing required proteins.
However, these antiviral drugs have side effects such as an increase in potential infection rates and continuous occurrence of drug-resistant virus strains in a short time (Magden, et al., Appl Microbiol Biotechnol 66:612-621, 2005).
Antibodies, known as immune proteins, are widely used to treat viral diseases. But, clinical use of the antibodies is restricted to passive immunization which involves neutralization mechanism of antibodies against specific viruses. For example, palivizumab was known (Cardenas, et al., Expert Rev Anti Infect Ther 3:719-726, 2005), which is an antibody directed against an epitope in the A antigenic site of F-glycoprotein present in a respiratory syncytial virus (RSV) envelope.
U.S. Pat. No. 6,818,216 discloses novel anti-RSV antibodies which can permit administration of lower dosages owing to their superior affinities, compared to conventional anti-RSV antibodies.
However, these antibodies have fundamental problems in that variation in the antigen structure of genes by mutants inhibits the antibody from recognizing the antigen any more, thus making it impossible to realize antiviral activity of the antibody specific for the antigen.
The reason for such a problem is that developments of antiviral antibodies are targeted on viral gene products. An alternative to solve this problem is to develop viral nucleic acid-targeting antibodies. However, there is no antibody associated with the alternative reported to date. A nuclease was reported as an enzyme degrading nucleic acid. The nuclease transferred into host cells is very cytotoxic to the cells and thus causes the fundamental problem of cell death. Such a problem inevitably restricts the developments of viral nucleic acid-targeting antibodies.
Meanwhile, there are only a few of antibody proteins known as catalytic antibodies that bind to antigens and at the same time exhibit enzymatic activities on the antigens. Some anti-DNA, anti-RNA and anti-DNA/RNA antibodies are known as naturally-generating catalytic antibodies (Buneva, et al., Appl Biochem Biotechnol 75: 63-76, 1998; Jang, et al, cell Mol Life Sci 60:309-320, 2003).
In addition, the only anti-DNA catalytic antibody known in the art is BV04-01 that has a structure based on recombinant single-chain variable fragment (scFv) and exhibits catalytic activity as an anti-DNA catalytic antibody degrading single- and double-strand DNAs (Gololobov, et al., Mol Immunol 34:1083-1093, 1997).
However, RNase activity, anti-virus activity on animal cells and protection possibility of self-derived nucleic acid of BV04-01 were not reported at all.
DISCLOSURE OF INVENTION Technical ProblemIt is one aspect of the present invention to provide a novel antiviral agent that has degrading ability selective for foreign nucleic acid chains invaded in an animal cell, and has no cytotoxicity to the animal cell itself, thus causing no death of the animal cell.
It is another aspect of the present invention to provide an antiviral animal cell that has degrading ability selective for foreign nucleic acid chains, and has no cytotoxicity on the animal cell itself, thus causing no death of the animal cell.
Technical SolutionIn accordance with one aspect of the present invention for achieving the above aspect, there is provided an antiviral agent against animal viruses, the antiviral agent containing, as an active ingredient, a protein that has binding and degrading abilities selective for foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself.
In accordance with another aspect of the present invention, there is provided an antiviral agent against animal viruses containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding and degrading abilities selective for foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself.
In accordance with another aspect of the present invention, there is provided an antiviral animal cell containing, as an active ingredient, a protein that has binding and degrading abilities selective for foreign nucleic acid chains introduced into an animal cell and that has no cytotoxicity to the animal cell itself.
In accordance with yet another aspect of the present invention, there is provided an antiviral animal cell containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding and degrading abilities selective for foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself.
Advantageous EffectsAs apparent from foregoing, the antiviral agent of the present invention is capable of selectively degrading foreign nucleic acid chains invaded in animal cells and has no cytotoxicity on the animal cells, thus exhibiting advantageous effects in that the host cells can be protected and the foreign nucleic acid chains only can be removed.
The above and other aspects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
The present invention will now be described with reference to the accompanying drawings in greater detail.
The present invention provides an antiviral agent containing the protein according to the present invention or a nucleic acid sequence encoding the protein, as an active ingredient, and an antiviral animal cell containing the protein according to the present invention or a nucleic acid sequence encoding the protein as an active ingredient.
In one aspect, the present invention is directed to an antiviral agent against animal viruses containing, as an active ingredient, a protein that has binding and degrading abilities selective for foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself, and to an antiviral agent against animal viruses containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself.
In another aspect, the present invention is directed to an antiviral animal cell containing, as an active ingredient, a protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and that has no cytotoxicity to the animal cell itself, and to an antiviral animal cell containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in the animal cell and that has no cytotoxicity to the animal cell itself.
According to the present invention, the protein used for the antiviral agent and the antiviral animal cell must be capable of binding to foreign nucleic acid chains and degrading the chains while having no cytotoxicity to the animal cell.
As one example of proteins that meet these requirements, separated and purified 3D8 proteins were evaluated for antiviral activity against animal viruses. As can be seen from the following Example 1, the evaluation results demonstrated that the 3D8 proteins exhibit antiviral activity against animal viruses and have no cytotoxicity.
The term “binding ability to foreign nucleic acid chains” herein used refers to an ability of proteins that can recognize nucleic acid (such as DNA and RNA) chains and bind to the nucleic acid chains. The binding of proteins to nucleic acid chains is based on the couplings between positive charges in amino acids constituting proteins and negative charges in phosphate backbones of DNA or RNA.
Anti-nucleic acid antibodies and nucleases are generally bound to DNA or RNA by recognizing specific sequences of the DNA or RNA. As apparent from Experimental Examples 2 and 5, the protein of the present invention is bound to nucleic acid chains without any sequence specificity, thus being widely utilized in the research fields associated with nucleic acid degradation activity.
The term “degrading ability to foreign nucleic acid chains” herein used refers to an ability of proteins that can cleave nucleic acid such as DNA and RNA chains by hydrolysis. This term is also called a “catalytic ability”.
Meanwhile, the term “cytotoxicity” herein used refers to a phenomenon in which cells are killed by invading foreign materials. DNases (DNA-degrading enzymes) and RNases (RNA-degrading enzymes) are generally cytotoxic.
On the other hand, the protein of the present invention is characterized in that it has no cytotoxicity to self-derived cells.
The nucleic acid sequence encoding a protein that has binding and degrading abilities to foreign nucleic acid chains introduced into animal cells and has no cytotoxicity to the animal cells may be either a RNA or DNA sequence. Preferred is the DNA sequence in view of stability.
The DNA sequence may be a nucleic acid sequence introduced into vectors capable of expressing genes in animal cells. As can be confirmed from Example 4, the introduction of genes having such a DNA sequence into animal cells leads to efficient expression of proteins and exhibition of efficacious antiviral activity.
It is preferable that the protein capable of binding to invading foreign nucleic acid chains and degrading the chains and having no cytotoxicity to the animal cell itself, which is used for the antiviral agent and the antiviral animal cell according to the present invention, is obtained from autoimmune disease-induced animals. This is the reason that proteins bound to nucleic acids or reacted therewith are known to be intimately associated with autoimmune diseases. In the present invention, there is no particular restriction as to the animal. Any animal may be used without particular limitation so long as it naturally induces an autoimmune disease. Preferred is the use of a mouse.
Of the genes inducing an autoimmune disease to such an animal, an Ipr gene is preferably malfunctioned.
Animals having malfunctioned Ipr genes are liable to suffer from autoimmune diseases. For this reason, the protein having binding and degrading abilities to foreign nucleic acid chains, while having no cytotoxicity to the animal cell, can be readily obtained from the Ipr gene-malfunctioned animals.
Ipr genes mediate production of Fas proteins which are one of the major factors causing apoptosis. The Fas proteins mediate cell apoptosis on the surface of cells. When the Fas proteins are activated, cells begin to undergo the apoptosis mechanism. On the other hand, when Ipr genes are injured, formation of Fas proteins is inhibited and normal cell apoptosis thus does not occur. Such a mechanism suppresses removal of lymphocytes capable of attacking self-cells, thus leading to an autoimmune disease.
As the protein that is capable of binding to foreign nucleic acid chains invaded in an animal cell and degrading the nucleic acid chains and has no cytotoxicity to the animal cell, immunoglobulin or a fragment thereof may be used that has binding and degrading abilities specific for foreign nucleic acid chains. The immunoglobulin may be preferably immunoglobulin G (IgG). More preferably, the IgG may be a 3D8 protein.
“Immunoglobulin” herein used is a generic term for proteins that are serum ingredients playing an important role in immunity and acting as antibodies. Such immunoglobulin consists of a pair of light chains (CL) having a molecular weight of about 23,000 and a pair of heavy chains (CH) having a molecular weight of about 50,000 to 70,000 which are connected by disulfide bonds. The type of heavy chains denoted by γ, α, μ, δ and ε defines the class of antibody, i.e., IgG, IgA, IgM, IgD and IgE, respectively.
IgG consists of a pair of light chains having a molecular weight of about 25,000 and a pair of heavy chains having a molecular weight of about 50,000, and has a total molecular weight of 150,000.
IgG is an immunoglobulin essential in the higher animals (amphibian or higher), takes about 70% of overall human immunoglobulins, passes through placenta and exhibits a variety of antibody activities.
Meanwhile, any immunoglobulin fragment may be used singly or in combination thereof so long as it is capable of binding to nucleic acid chains and degrading the chains. Preferred is one selected from scFv, VH, VL, and Fv with an association of VH and VL.
A scFv (single chain fragment variable) is a fusion of a variable heavy (VH) chain and a variable light chain (VL), linked through a linker. Such a scFv was known to have a strong antigen-binding force, compared to VH or VL used singly. The linker that mediates the binding between VH and VL may be of any type commonly used in the art.
As mentioned above, the antigen-binding force of VH or VL is generally known to be inferior to that of scFv. However, preferred is VH or VL in some cases where improvement in permeability into the tissue is intended.
Preferably, the scFv may have a sequence set forth in SEQ ID NO 6, the VH may have a sequence set forth in SEQ ID NO 2 and the VL may have a sequence set forth in SEQ ID NO 4.
In connection with the nucleic acid chain-binding ability and nucleic acid chain-degrading ability required for the protein according to the present invention, any protein may be used to obtain intended effects of the present invention so long as it has either binding/degrading abilities specific for RNA or binding/degrading abilities specific for DNA. This is the reason that proteins having binding and degrading abilities specific for RNA chains only can be applied to RNA viruses only and proteins having binding and degrading capabilities specific for DNA only chains can be applied to DNA viruses only.
More preferred is the use of proteins that have binding and degrading abilities to both DNA and RNA chains in that they are applicable to both RNA viruses and DNA viruses.
In the present invention, there is no particular restriction as to the virus invaded in the animal cells. Specifically, the virus may be RNA-based virus, and more specifically may be HIV virus or SARS virus.
In an attempt to ascertain whether or not the protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in animal cells and that has no cytotoxicity to the animal cells itself exhibits anti-virus activity against animal viruses as explained above, VH, VL and scFv domains of 3D8 antibodies (IgG) obtained in accordance with the method of Preparative Example 1 were used as one example. The VH, VL and scFv domain antibodies were obtained from 3D8 hybridoma cells in accordance with the method of Preparative Example 2. These antibodies were used following over-expression in E. coli and purification.
In Experimental Example 1, the existence-form of VH and VL proteins and association therebetween were investigated. The investigation results ascertained that both VH and VL proteins exist in the form of monomers, not multimers, and VH and VL are naturally associated with each other to form Fv.
In Experimental Example 2, DNA-binding capacity and characteristics of the VH,
VL and scFv proteins were investigated. From evaluation results, it can be confirmed that all of the three antibody proteins (scFv, VH and VL antibody proteins) have a considerably high binding force with ssDNA and dsDNA. The DNA-binding affinity of scFv was 100-fold to 1,000-fold higher than those of VH and VL. This result shows that DNA-affinities of proteins where VH and VL domains coexist are superior to those of proteins where VH and VL domains separately exist.
In Experimental Example 3, DNA-degrading activity and substrate-specificity of the VH, VL, and scFv antibody proteins were evaluated. DNase activity of the antibody proteins in the presence of magnesium ions (Mg2+) was in the order of scFv<VL>>VH. On the other hand, in the presence of EDTA, DNase activities of all proteins were inhibited. In particular, it was confirmed from agarose gel electrophoresis assay that ss M13mp18 DNAs as well as ds M13mp18 DNAs were degraded by the proteins with the process of time.
Affinity-linked oligonucleotide nuclease assay (ALONA) was used to probe s ubstrate-specificity of DNase activity. The scFv, VH and VL proteins substantially exhibited no DNA-substrate specificity on DNase activity.
It was confirmed from Experimental Example 4 that scFv, VH and VL proteins degrade DNAs through different mechanisms.
As one example of proteins that have binding ability and degrading ability to foreign nucleic acid chains invaded in animal cells and have no cytotoxicity to the animal cells itself, 3D8 scFv proteins were used to evaluate RNase activity. As a result of Experimental Example 5, it can be confirmed that the scFv proteins exhibited RNase activities on dsRNAs as well as on ssRNAs, depending on the reaction time. The substrate-specificity assay results indicated that scFv antibody proteins are capable of degrading RNA/DNA hybrids as well as ssRNAs and dsRNAs on RNase activities.
In Example 1, after 3D8 scFv protein-injected animal cells are transfected with vesicular stomatitis virus, antiviral activity of 3D8 scFv protein against the virus was confirmed. As a result, it can be confirmed that animal cells, into which no 3D8 scFv protein is introduced, underwent cell death which is one of cytopathic effects (CPEs) by VSV (
3D8 scFv protein-transferred Hela cells into which no VSV is infected had no inherent cytotoxicity of the 3D8 scFv protein. On the other hand, RNase A-transferred Hela cells (VSV non-transfected) as a control group wholly underwent death due to inherent cytotoxicity of the RNase A.
These results indicated that antiviral activities of the 3D8 scFv proteins are remarkably greater than those of conventional nucleases, and the protein having binding ability and degrading ability to foreign nucleic acid chains introduced into animal cells, while having no cytotoxicity to the animal cells itself, exhibits anti-virus activity against animal viruses.
The results obtained from Example 2 ascertained that 3D8 VH and VL proteins as well as 3D8 scFv proteins exhibited antiviral activities against animal cells.
Even in a case where nucleic acid sequences encoding the protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in animal cells and has no cytotoxicity to the animal cells were invaded in animal cells, the nucleic acid sequences are proven to exhibit anti-virus activity against virus-infected animal cells. Specifically, it can be confirmed from Example 4 that 3D8 scFv gene-transfected animal cells also produce scFv proteins and also exhibit resistance against various viruses.
Hereinafter, the formulation and administration methods of the antiviral agent against animal viruses according to the present invention will be given below.
<Formulation and Administration: Antiviral Agent Against Animal Viruses Containing, as an Active Ingredient, a Protein Having Binding and Degrading Abilities to Foreign Nucleic Acid Chains Invaded in an Animal Cell and Having No Cytotoxicity to the Animal Cell Itself>
The antiviral agent against animal viruses containing the protein according to the present invention as an active ingredient is capable of selectively degrading invaded foreign nucleic acid chains and has no cytotoxicity to the animal cell itself. Specifically, the antiviral agent of the present invention is capable of removing invading-foreign viruses only, while not killing self-cells, thus being useful for virus-mediated diseases such as acquired immunodeficiency syndrome (AIDS). More specifically, the treatment of the diseases affects virus-infected cells and thus prevents death of the cells.
The antiviral agent according to the present invention contains, as an active ingredient, a protein that has binding ability and degrading ability to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself.
The expression “antiviral agent contains protein as an active ingredient” means that the protein is added to the antiviral agent in an amount such that the protein can exert desirable antiviral activity, and that, in a broad sense, the protein is formulated in a variety of dosage forms together with various adjuvants for drug delivery and stabilization.
Preferably, the protein may include immunoglobulin or a fragment thereof that has binding/degrading abilities to foreign nucleic acid chains. More preferably, the immunoglobulin may be immunoglobulin G (IgG). Most preferably, the IgG may be a 3D8 protein. Preferably, the immunoglobulin fragment may be one selected from scFv, VH, VL, and Fv with an association of VH and VL.
The antiviral agent of the present invention may further comprise a pharmaceutically acceptable carrier or additive (generally, a buffer solution, an isotonic solution, an aqueous suspension or the like, and optionally, a stabilizer, an antiseptic, or the like). Formulations generally comprise saline and optionally protected or stabilized molecules such as a high molecular weight of proteins (e.g., human serum albumin).
The protein that has binding and degrading abilities to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself, preferably IgG or a fragment thereof, is administered to a receptor in a dosage rendering the protein to be “effective” or “efficacious for treatment”.
The effective dosage of the protein administered to a receptor may be in a range of about 0.1 □/kg to about 20 □/kg. Generally, the effective dosage of proteins is determined by various factors such as protein type (e.g., overall IgG or fragments thereof), affinities and individual characteristics of specific therapeutic proteins and depends on pharmacokinetic parameters. Accordingly, the effective dosage of the protein according to the present invention may depend on these various factors.
According to main embodiments of the present invention, the use of the protein-containing antiviral agent enables of realization the desirable treatment efficacy despite of administration of the therapeutic protein in a reduced dosage.
In addition, the use (e.g., dosage and prescription designs) of the therapeutic protein of the present invention may be restricted by undesired side effects (e.g., pyrexia, headache, gasp, blood pressure drop, and the like).
Accordingly, a standard dosage of therapeutic proteins administered to the patients may be varied according to individual characteristics of patients. In practice, a skilled clinical physician may design the most preferable therapeutic strategies (e.g., optimal dosage and dose regimen) for patients taking into consideration factors e.g., specific necessities and overall conditions of the patients. Suitable dosages of therapeutic proteins may be determined in accordance with various references.
According to one embodiment of the present invention, a physician may gradually reduce a given amount of therapeutic proteins while administrating the protein-containing antiviral agent of the present invention to patients. After monitoring the efficiencies of therapeutic proteins, activities of virus-defected cells and a variety of therapeutic symptoms, while taking into consideration the dosage and administration frequency, the relative concentration and dose form of therapeutic proteins may be controlled to optimize therapeutic efficacy and minimize side effects.
Meanwhile, the therapeutic protein of the present invention may be generally determined in vitro or by an animal model. For example, an optimal dosage may be determined by in vitro introducing various concentrations of therapeutic proteins of the present invention into target cells (virus-infected cells), followed by evaluating a death ratio of the target cells.
The therapeutic protein-containing antiviral agent according to the present invention may be directly administered to subjects by intravenous, intraperitoneal, intraarterial, intramuscular or intradermal injection.
Monoclonal antibodies such as rituxan (marketed under the name of Rituximab™) and omalizumab (marketed under the name of Xolair™) were efficacious in clinical treatments and equivalent prescription regimes (i.e., formulation and/or dosage and/or dose protocol) may be used for the therapeutic protein-containing antiviral agent according to the present invention.
The antiviral agent according to the present invention may be simultaneously or sequentially used in conjunction with chemotherapies or therapeutic programs for treating viral diseases or a combination thereof.
<Formulation and Administration: Antiviral Agent Against Animal Viruses Containing, as an Active Ingredient, a Nucleic Acid Sequence Encoding a Protein that has Binding and Degrading Abilities to Foreign Nucleic Acid Chains Invaded in an Animal Cell and has No Cytotoxicity to the Animal Cell Itself>
Expression of DNA sequences, as nucleic acid sequences encoding proteins, may be carried out using individual expression vectors or a single expression vector.
Preferably, the nucleic acid sequence encoding the protein according to the present invention includes immunoglobulin or a fragment thereof that has binding/degrading abilities to foreign nucleic acid chains. More preferably, the immunoglobulin may be immunoglobulin G (IgG). Most preferably, the IgG may be a 3D8 protein. In addition, the immunoglobulin fragment may be nucleic acid encoding one fragment selected from scFv, VH, VL, and Fv with an association of VH and VL.
If a single vector is employed for each sequence, respectively, the vectors may be mixed before injection and electroporation, in order to allow individual muscle cells to take up and express each of the vectors.
The term “expression vector” herein used refers to a plasmid or vehicle that is manipulated by insertion or incorporation of a polypeptide-encoding nucleic acid and that is capable of directing the expression of the polypeptide when the vector is in an appropriate environment.
A suitable expression vector typically includes a promoter, an origin of replication, a poly-A recognition sequence, and a ribosome recognition site or internal ribosome entry site, and may include other regulatory elements such as an enhancer (tissue-specificity).
The promoter, which facilitates the efficient transcription of the inserted encoding nucleic acid sequence in muscle, can be constitutive or, if desired, inducible, tissue specific or developmental stage specific. Examples of promoters useful for the present invention include promoters normally functioning in muscles such as the skeletal actin gene promoter (Muscat, et al., Mol. Cell. Biol. 7, 4089 (1989)), the muscle creatine kinase promoter (Sternberg, et al., Mol. ell. Biol., 8, 2896 (1988)) and the myosin light chain enhancer/promoter (Donoghue, et al, Proc. Natl. Acad. Sci., USA 88, 5847 (1991)).
A preferred expression vector comprises an expression cassette that has multiple endonuclease restriction sites allowing ready cloning of DNA encoding different polypeptides into the cassette in a manner that places the encoding DNA in operative linkage with the promoter or other transcriptional regulatory elements of the vector. A preferred expression vector also may have an origin of replication for a procaryotic cell and at least one selective marker to aid in cloning in such a cell. Those skilled in the art would know how to optimize expression by selecting a vector properly configured with the appropriate combination of promoter, enhancer and other transcriptional or translational regulatory element for the polypeptide(s) to be expressed in muscle.
The methodology of the present invention allows for multi-chain protein expression from skeletal muscles, smooth muscles, and cardiac muscles, respectively. Expression following injection of skeletal muscle is preferred because of the abundance and ready access of this muscle source. For skeletal muscle, the expression vector may be injected through the skin and into the skeletal muscle via traditional means such as a syringe and needle, or by a needle-less injection device. Such latter devices are well-known in the art and, generally, involve pressure-assisted delivery through a tiny orifice held against the skin.
The injection apparatus may be suitably selected with reference to U.S. Pat. No. 4,596,556 issued to Morrow, et al; U.S. Pat. No. 4,913,699 issued to Parsons; and U.S. Pat. No. 5,730,723 issued to Castellano, et al. Another available commercially injection apparatus is BIOJECT™ (available from Bioject Medical Technologies, Inc., Portland Oreg. U.S.A.). Another needless injection apparatus is a gene gun delivery system that uses pressurized gas to deliver small particles (e.g., gold particles) into the targeted skin site, as a function of the gas pressure. An example of a biolistic delivery device is PDS-1000 “gene gun” (marketed by Dupont, Inc., Wilmington, Del., U.S.A.).
Expression vectors can be administered in 0.9% sodium chloride, however, there are a variety of solvents and excipients that may be added without taking any effect on the expression level. For example, it is well known in the art that sucrose is capable of increasing DNA uptake in skeletal muscles.
The animal cell exhibiting antiviral efficiencies against animal viruses according to the present invention may be utilized as an experimental use and as a cell medication according to well-known methods.
Mode for the InventionThe present invention will be explained in more detail with reference to the following Examples (Preparative Examples, Experimental Examples and Examples). The scope of the invention is not necessarily limited to these examples and intended to incorporate modifications with equivalent technical ideas.
EXAMPLES Preparative Example 1 Establishment of 3D8 Hybridoma Cell LinesSpleen cells of MRL-lprllpr mice (available from Jackson Laboratory, U.S.A.) and V653 cells (available from the Korean cell line bank) were fused with polyethylene glycol (PEG) 4000 and cultured in a hypoxanthine-aminopterin-thymidine (HAT) medium (available from Sigma-Aldrich, Inc.) in a 5% CO2 incubator at 37° C. for 15 days. During the culturing, antibodies having DNA-binding ability were selected by enzyme-linked immunosorbent assay (ELISA).
The cell lines were cultured twice by limiting dilution to obtain about ten kinds of hybridoma cell lines that secrete anti-DNA antibodies. The anti-DNA antibody-secreting cell line that shows the greatest DNA-binding capacity was selected from the hybridoma cell lines by ELISA. The selected cell line was deposited at the Korean Cell Line Research Foundation (KCLRF) on Sep. 13, 2006 (Accession No: KCLRF-BP-00146).
The isotype of the antibody the selected hybridoma cell line secretes was detected using an isotype detection kit (Pierce, Inc.). As a result, the antibody derived from the cell line was determined to be IgG2a/kappa and was called “3D8”.
Preparative Example 2 Cloning of Heavy-Chain (VH) and Light-Chain (VL) Variable Domain Genes from the 3D8 Hybridoma Cell LineAbout 1×106 of the hybridoma cells obtained in Preparative Example 1 were dissolved in 0.2 ml of an RNA extraction reagent (RNAzo1 B™; TEL-TEST, Inc.) and homogenized. 0.02 ml of chloroform was added to the solution, thoroughly stirred for 15 seconds and allowed to stand in an ice bath for 5 minutes. The resulting solution was centrifuged and the resulting supernatant was then separated. 0.25 mL of ethanol was added to the residue, allowed to stand at 4° C. for 15 minutes and was then centrifuged (at 12000 g, 4° C.) for 15 min. The resulting RNA precipitate was washed with 70% ethanol, dried and dissolved in distilled water. The absorbance of the RNA at 260 nm and 280 nm was measured and a purity and yield of the RNA were determined.
cDNAs were synthesized from the RNA thus obtained using a RT-PreMix kit (Bioneer Inc.). At this time, oligo-(dT) oligonucleotide was used as a primer. VH and VL genes were amplified with a polymerase chain reaction (PCR) method using the cDNAs as templates.
The primer set used for VH gene amplification is as follows:
The VH gene amplification was carried out by a touchdown PCR for 30 cycles using a Taq DNA polymerase. The touchdown PCR conditions (in each cycle) were given as follows: at 94° C. for one min→decreasing 0.5° C. per cycle (from an initial annealing temperature (65° C.) for one min→at 72° C. for one minute.
The primer set used for VL gene amplification is as follows:
The VL gene amplification was carried out by a touchdown PCR for 30 cycles using a Taq DNA polymerase. The touchdown PCR conditions (in each cycle) were given as follows: at 94° C. for one min→decreasing 0.3° C. per cycle (from an initial annealing temperature (63° C.) for one min→at 72° C. for one minute.
Respective PCR reaction solutions were subjected to electrophoresis with a 1% agarose gel, and VH and VL genes were extracted from the gel and cloned in pGEM-T Easy vectors (available from Promega Corp.). The base sequence of the cloned genes was analyzed by a Perkin Elmer 373A automated DNA sequencer (Applied Biosystems, Inc.).
The primer set used for the base seauence analysis is as follows:
From the base sequence analysis results, it can be confirmed that the base sequence of the VH genes was the same as set forth in SEQ ID NO 1, the amino acid sequence of the VH genes was the same as set forth in SEQ ID NO 2, the base sequence of the VL genes was the same as set forth in SEQ ID NO 3 and the amino acid sequence of the VL genes was the same as set forth in SEQ ID NO 4. Blast search results ascertained that no such a base sequence was reported to date.
Preparative Example 3 Sub-Cloning of VH, VL and scFv (Single Chain Fragment Variable) Domain Genes in Bacteria Expression VectorsTo express VH or VL proteins in bacteria, VH and VL genes obtained in Preparative Example 2 were cloned in pIg20H and pIg20L vectors (available from the professor, Stollar B D, Tufts University, U.S.A). A primer containing an XmaI/XbaI fragment as a restriction enzyme recognition site was prepared and used for the VH cloning. Meanwhile, a primer containing a BglII/NcoI fragment as a restriction enzyme recognition site was prepared and used for the VL cloning.
To manufacture a scFv construction, VH and VL genes separately cloned on the pGEM-T Easy vector (Promega Corp.) were sequentially sub-cloned in pIg20 expression vectors (available from the Professor, Stollar B D, Tufts University, U.S.A.) containing a linker DNA (decoded as “GGGGS3”). The base sequence of the primer used herein is as follows:
As a result of the sub-cloning, pIg20H-3D8 VH, pIg20L-3D8 VL and pIg20-3D8 scFv vectors were obtained (The base sequences of scFv genes cloned in the pIg20 vector are shown in
In order to purify VH, VL and scFv proteins, pIg20H-3D8 VH, pIg20L-3D8 VL, and pIg20-3D8 scFv vectors were transformed into E. coli BL21 (DE3) pLysE cells (available from Novagen Inc.) and cultured in a LB culture medium containing 100 □/ml of ampicillin and 20 □/ml of chloramphenicol until the absorbance (A600) reached 0.8. 0.5 mM of isopropyl-β-D-thiogalactopyranoside (IPTG) was added to the culture medium and further cultured at ambient temperature for 4 hours. The cultured cells were centrifuged (at 10,000×g, 4° C.) for 10 min and the resulting supernatant was filtered through a 0.45 □ filter membrane. The filtrate was passed though an IgG-sepharose column (Amersham pharmacia Biotech Ltd.) at a flow rate of 1 ml/min, washed with a phosphate buffer solution (PBS, pH 7.4) and ammonium acetate (pH 5.0), and eluted with 0.1 M acetic acid (pH 3.4). The eluted proteins were dialyzed against a PBS and were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reduction conditions to determine the purity of the proteins.
The purified VH, VL, scFv and Fv (defined as a variable fragment having a non-covalent bond between VH and VL) proteins were subjected to size exclusion chromatography (SEC) using a HPLC system. 0.02 ml of a protein (conc. 5-20 μM) was injected into a TSK G3000SWXL column (TosoHaas, Japan) and a phosphate buffer solution (50 mM sodium phosphate/150 mM NaCl, pH 7.4) was flowed therein at a flow rate of 0.7 ml/min and the chromatogram of the proteins was obtained from the absorbance at 280 nm.
Under the phosphate buffer solution conditions, both VH and VL proteins exist in the form of monomers, and neither VH nor VL in the form of a multimer was observed (
In addition, a VH-VL associated Fv was seen from
The quantitative binding capacity of the purified VH, VL and scFv proteins with DNAs with various base sequences was evaluated by surface plasmon resonance (SPR) analysis.
A 40-mer synthetic DNA fragment containing a biotin-labeled 3′-terminal was immobilized onto a streptavidin-coated sensor chip, scFv (5-200 nM), VH (0.2-50 μM) and VL (1.6-200 μM) proteins previously diluted with a HES buffer (10 mM HEPES, pH 7.4 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20) were flowed to the chip at a flow rate of 50 □/min for 3 min and a HES buffer was further flowed thereto at a flow rate of 50 □/min for 3 min to induce dissociation of the proteins linked to the DNAs.
The sensorgram analysis ascertained that all of the three antibody proteins (scFv,
VH and VL antibody proteins) have a considerably high binding capacity with ssDNA and dsDNA. The high binding capacity indicates that scFv, VH and VL antibody proteins hardly have base sequence specificity for DNAs (
To ascertain the fact that non-specific DNA binding of the scFv, VH and VL proteins was mainly caused by electrostatic force, ELISA was performed using single-stranded (ss(N)40) or double-stranded (ds(N)40) nucleic acid having a 40-mer pre-determined base sequence as a substrate in the presence of various concentrations (from 0 M to 0.8 M) of NaCl.
It can be seen from ELISA results that as a NaCl concentration increases, all of the three proteins underwent a decrease in DNA-binding affinity to 50 to 90%. This behavior indicated that binding of antibody proteins to DNAs was mainly caused by electrostatic force. (In
The purified scFv (0.8 μM), VH (5 μM) and VL (5 μM) proteins were reacted with 300 ng of plasmid M13mp18 (available from New England Biolabs, Ltd) in the presence of a TBS solution (20 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM MgCl2) for 1 to 12 hours. The reaction mixture was treated with trypsin and subjected to agarose gel electrophoresis.
A TBS solution containing 50 mM EDTA, instead of the MgCl2, was added to the resulting to ascertain magnesium ion (Mg2+) dependency of DNase activity.
DNase activity of each protein in the presence of magnesium ions (Mg2+) is in the order of scFv>VL>>VH. On the other hand, in the presence of EDTA, DNase activities of all proteins were inhibited. In particular, as can be seen from the results of agarose gel electrophoresis, ss M13mp18 DNAs as well as ds M13mp18 DNAs were degraded with the process of time (
Affinity-linked oligonucleotide nuclease assay (ALONA) was used to probe substrate-specificity of DNase activity. Oligonucleotides having a digoxigenin-labeled 5′-terminal and a biotin-labeled 3′-terminal, i.e., ss-(dT)40, ds-(dT:dA)40, ss-(dN)40, ds-(dN:dN′)40, ss-(dG-dC)20, and ds-(dG-dC:dC-dG)20 were immobilized on a streptavid in-coated 96-well culture plate through biotin-streptavidin bindings, and allowed to react with 3D8 scFv (0.8 μM), Fv (5 μM), VH (5 μM) and VL (5 μM) in a MgCl2-containing TBS solution (2 mM) at 37° C. for 10 hours. The ss-(dT)40 herein used refers to a single-stranded nucleic acid consisting of thymine. The ds-(dT:dA)40 herein used refers to a double-stranded nucleic acid consisting of 40-mer thymines and 40-mer adenines. The ss-(dN)40 herein used refers to a single-stranded nucleic acid consisting of 40-mer specific bases. The ds-(dN:dN′)40 herein used refers to a double-stranded nucleic acid in which one 40-mer bases are complementarily bound to another 40-mer bases. The ss-(dG-dC)20 herein used refers to a 20-mer single-stranded nucleic acid in which guanine is alternatively linked to cytosine. The ds-(dG-dC:dC-dG)20 herein used refers to a double-stranded nucleic acid in which a 20-mer guanine-cytosine strand is linked to a 20-mer cytosine-guanine strand.
The remaining DNAs were reacted with alkaline phosphatase-linked anti-digoxigenine antibodies and a p-NPP solution (1 mg/ml p-NPP in 0.1 M glycine, 1 mM ZnCl2, 1 mM MgCl2, pH 10.3) was added thereto as a substrate of alkaline phosphatase. The absorbance at 405 nm was measured (
The comparison in three-dimensional structure between the 3D8 scFv antibody proteins of the present invention and BV04-01/ss-(dT)3 as a conventionally known anti-DNA catalytic antibody (
On the basis of such presumption, His35 of VH and His94 of VL (i.e., residues represented by the numbers “35” and “94” in
The DNase activities of the proteins were evaluated in the same manner as Experimental Example 3.
As a result, the substitution of His residues in scFv proteins took no great effect on
DNA bindings (
On the other hand, the substitutions of His residues in VH and VL proteins hardly affected DNA-binding ability and DNase activity. These behaviors mean that DNA degradation mechanisms of VH and VL proteins are different from those of scFv proteins (
In
DNA; the term “lin” is an abbreviation for a “linear form” and refers to a linear DNA; the term “sc” refers to an abbreviation for “supercoiled form” and refers to a completely coiled DNA.
In
To evaluate RNase activities of the 3D8 scFv proteins, ssRNA and dsRNA substrates were primarily prepared.
The ssRNAs were prepared by synthesizing ssRNAs through in vitro transcription using a T7 promoter of tobacco mosaic virus-coat protein (TMV-CP) gene-cloned pLITMUS vectors (available from New England BioLabs, Inc.), followed by purification.
The dsRNAs were obtained by synthesizing ssRNAs through in vitro transcription using T7 and SP6 promoters of pLITMUS vectors, followed by purification and hybridization.
300 ng of the ssRNAs (or dsRNAs) thus prepared were reacted with 0.8 μM of scFv proteins in a TBS solution for 1 to 5 hours and subjected to agarose gel electrophoresis. From the agarose gel electrophoresis results, it can be confirmed that the scFv proteins exhibited RNase activities on dsRNAs as well as ssRNAs, depending on the reaction time (
To ascertain the assumption that the RNase activity of 3D8 scFv proteins was attributed to scFv's inherent nature, not by-products contaminated during the protein purification, in situ hydrolysis assay of the 3D8 scFv proteins was conducted. That is, 3D8 scFv proteins were subjected to SDS-PAGE on an acrylamide gel containing 20 □/ml of dsRNA or 20 □/ml of ssRNA. The gel was washed with 7 M for one hour and allowed to stand in a Tris solution (10 mM Tris, pH 8.0, 10 mM MgCl2, 50 mM NaCl) at 37° C. for overnight. The gel was sequentially stained with ethidium bromide and coomassie blue. It was observed that RNAs were degraded in a region only where there are proteins and thus not stained with ethidium bromide. (In
The substrate specificity of RNase activity was probed by affinity-linked oligonucleotide nuclease assay (ALONA) in the same manner as in Experimental Example 3, except that oligonucleotides having a digoxigenin-labeled 5′-terminal and a biotin-labeled 3′-terminal, i.e., ss-(rU)40, ds-(rU:rA)40, and ds-(rU:dA)40 (RNA/DNA hybrid) were used as substrates.
These substrates were immobilized onto a streptavidin-coated 96-well culture plate through biotin-streptavidin bindings and allowed to react with 0.8 μM of 3D8 scFv proteins in a MgCl2-containing TBS solution (2 mM) at 37° C. for 10 hours.
Meanwhile, a TBS solution containing 50 mM EDTA, instead of MgCl2, was added to the resulting to ascertain magnesium divalent ion (Mg2+)-dependency of Rnase activity.
The ss-(rU)40 herein used refers to a single-stranded nucleic acid consisting of 40-mer ribouracils. The ds-(rU:rA)40 herein used refers to a double-stranded nucleic acid consisting of 40-mer ribouracils and 40-mer riboadenines. The ds-(rU:dA)40 herein used refers to a double-stranded nucleic acid in the form of a RNA/DNA hybrid consisting of 40-mer ribouracils and 40-mer deoxyribose adenines, arranged such that ribouracil is alternatively linked to deoxyribose adenine.
The remaining RNAs and RNA/DNA hybrid were reacted with alkaline phosphatase-linked anti-digoxigenine antibodies, and a p-NPP solution (1 mg/ml p-NPP in 0.1 M glycine, 1 mM ZnCl2, 1 mM MgCl2, pH 10.3) was added thereto as a substrate of alkaline phosphatase. The absorbance of the resulting mixture at 405 nm was measured. The results are shown in
The results indicated that scFv antibody proteins are capable of degrading RNA/DNA hybrids as well as ssRNAs and dsRNAs, and the RNase activity of scFv antibody proteins is independent of Mg2+, which is different from DNase activity of the scFv antibody proteins.
The Mg2+-independent RNase activity is known to be observed on conventional RNases.
Example 1 Ascertainment of Antiviral Activity on 3D8 scFv Protein-Transferred Animal Cells by Fluorescence MicroscopyThe 3D8 scFv antibodies thus expressed in bacteria and purified were fluorescence-labeled with an Alexa 488 labeling kit (Molecular probes, Inc., green fluorescence). Then, the 3D8 scFv antibodies were injected into vero cells (African green monkey kidney cells) with a microporator (available from Digital Bio Technology Co., Ltd., Korea) under the electroporation conditions of voltage 100, pulse width 35 and pulse number 2. 20 □ of the scFv proteins were introduced into 2×16 of the vero cells, the protein-introduced cells were inoculated on a 48-well culture plate containing 0.5 ml of DMEM-10% fetal bovine serum, and the inoculated plates were incubated in a 5% CO2 incubator for 10 hours.
Substantially, the cells were transfected with vesicular stomatitis virus (VSV) having single RNA strand as genome in a 5% CO2 incubator for one hour at MOI 5 and were incubated in a new DMEM-10% fetal bovine serum medium.
After 24 hours, the cells were observed with a fluorescence microscope. From the fluorescence microscopy assay, it can be confirmed that vero cells, into which no 3D8 scFv protein was introduced, underwent cell death which is one of cytopathic effects (CPEs) by VSV (
In
The 3D8 scFv proteins were transfected into HeLa cells (human cervical carcinoma cell lines) by electroporation (voltage 1000, pulse width 35, pulse number 2) and transfected (infected) with VSV. It was observed that Hela cells showed antiviral activity, i.e., cell death inhibition, similar to the vero cells (See
In
On the other hand, all of HeLa cells (not transfected with VSV) transferred with RNase A died within 5 hours due to RNase A's inherent cytotoxicity.
This result showed that antiviral activities of the 3D8 scFv proteins are remarkably greater than those of conventional nucleases.
Example 2 Quantitative Assay of Antiviral Activity on 3D8 scFv, VH or VL Protein-Transferred Animal CellsThe antiviral activities of 3D8 scFv, VH and VL proteins were quantitatively ascertained by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay.
These proteins, bovine serum albumin (BSA) and lysozyme as control groups were electroporated into HeLa cells at 20 □/2×105 cells, divided onto 96-well culture plates at 1×105 cells/well, and incubated in a 5% CO2 incubator for 24 hours.
A protein-free HeLa cell subjected to electroporation only was used as another control group. After 24 hours, the protein-free HeLa cell group was transfected with VSV (at MOI=1) for one hour and cultured in a new medium for 24 hours.
When the protein-free HeLa cells are observed by fluorescent microscopy, a MTT solution (1 mg/ml PBS, 100 □) was added thereto and cultured in a 5% CO2 incubator for 4 to 5 hours.
The resulting fomazan was dissolved in 200 □ of dimethyl sulfoxide (DMSO). The absorbance of the fomazan was measured with an absorption spectrophotometer at 595 nm to determine the survival rate of the Hela cells.
As a result, the survival rate of the scFv, VH or VL protein-transferred HeLa cells was significantly higher than those of control groups. This result ascertained that all of scFv, VH and VL proteins have antiviral activities against VSV (See
The scFv, VH and VL proteins were electroporated into HeLa cells on 24-well culture plates at 20 □/2×16 cells/well and cultured in wells with a sterilized cover glass for 24 hours.
After completion of the culture for 24 hours, the cells were transfected with VSV for one hour and cultured in a new medium for 12 hours. To monitor proliferation of VSV fragments in HeLa cells by a confocal microscope, the immunofluorescence staining was conducted. Specifically, the medium was separated from each well, the cells were washed once with a PBS buffer solution containing 2% FBS, 400 □ of a fixation/permeabilization solution (Becton Dickinson, Inc.) was added thereto and allowed to stand at 4° C. for 20 min. The resulting cells were washed twice with a 2% FBS-containing PBS buffer solution, reacted with 500 □ of anti-VSV-FITC antibodies (1:1000 dilution) (Abcam, Inc.) at 4° C. for 40 min and washed three times with 2% FBS-containing PBS buffer solution.
A fixation solution (Invitrogen, Corp.) containing 3□ of DAPI (4′-6-Diamidino-2-phenylindole), as a regent that stains a cell nucleus blue in color, was added to a slide glass previously prepared, the slide glass was covered with the cell-adhered cover glass, the remaining adjacent region was sealed with the fixation solution, and VSV particles were observed with a confocal microscope.
From confocal microscopy monitoring, it can be confirmed that the amount of the VSV fragments present in cells, into which scFv, VH or VL proteins were transferred, was lower than that of the cells, into which scFv, VH or VL proteins were not transferred. This low amount of VSV fragments indicated scFv, VH and VL proteins inhibited VSV proliferation. (See.
In order to establish cell lines, in which 3D8 scFv proteins are stably expressed,
PCR was conducted with pIg20-3D8 plasmids to obtain 3D8 scFv genes and the 3D8 scFv genes were cloned into animal cell-expression vectors (
a) Cloning of 3D8 scFv proteins into pcDNA3.1 vectors
b) Cloning of 3D8 scFv proteins into pLXIN vectors
b) Cloning of 3D8 scFv proteins into pQCXIN vectors
(1) Establishment of 3D8 scFv Expressing-HeLa and NIH/3T3 Cell Lines by Simple Transfection
At 12 hours before HeLa cell lines and NIH/3T3 cell lines (mouse embryo fibroblasts) were transfected with pcDNA3.1-3D8 scFv vectors, the cell lines were cultured on 60 mm culture plates at 105 cells/well. The medium was replaced with a flesh one (DMEM-10% FBS) just before the transfection. 6 □ of a JetPEI transfection solution (Qbiogen, Inc.) and 3 □ of the pcDNA3.1-3D8 scFv vectors were homogeneously mixed with NaCl (1000, 150 mM) and allowed to stand at ambient temperature for 30 min. The resulting mixture was added to the HeLa cell lines or NIH/3T3 cell lines cultured on the 60 mm culture plates. After 24 hours, the used medium was replaced with a selective medium containing a G418 antibiotic (1 mg/ml), and substantially, replacement of the selective medium (at intervals of 2-3 days for 2 weeks) was continuously repeated to obtain colonies.
It was ascertained through reverse transcriptase-polymerase chain reaction (RT-PCR) that the colony-forming cells expressed 3D8 scFv mRNAs. The total cellular RNAs were extracted from the cells using a trizol solution (Invitrogen Life Technologies, Inc.), and cDNAs were synthesized from 3 □ of the extracted RNAs and subjected to polymerase chain reaction (PCR) using a RT-PCR PreMix kit (available from Bioneer, Ltd.).
As apparent from
Then, whether or not the transfected NIH3T3 cells expressed 3D8 scFv proteins was ascertained by immunofluorescence staining. That is, the cells were fixed by 4% paraformaldehyde, and were sequentially subjected to membrane-permeabilization using 0.1% Triton X-100 and membrane-blocking using a 5% skim milk (DIFCO, Inc.). The resulting NIH3T3 cells were reacted with rabbit-derived anti-3D8 scFv primary antibody (at a dilution of 1:50 in 3% skim milk-TBST) at ambient temperature for 30 min, washed twice with 3% skim milk-TBST, and reacted with TRITC-linked anti-rabbit IgG (1:2,000 dilution) at ambient temperature for 30 min and washed twice with a 3% skim milk-TBST.
Fluorescence microscopy assay results indicated that 3D8 scFv proteins were homogeneously expressed in the transfected NIH/3T3 cells (
In
The G418 were selected from 3D8 scFv-transfected HeLa cell lines and limiting dilution was performed on 96-well plates such that 0.5 cells are introduced into one well to establish monoclonal cell lines.
As shown in
Then, the expression of 3D8 scFv proteins in the two representative transfected-HeLa cell lines (H1-1 and H1-2) was ascertained by flow cytometry (
The flow cytometry analysis results showed that 3D8 scFv proteins were expressed in the transfected-HeLa cells (
(2) Ascertainment of 3D8 scFv-Expressing HeLa and PK15 Cell Lines Using Retrovirus Vectors:
The two retrovirus vectors i.e., pLXIN-3D8 scFv and pQCXIN-3D8 scFv, into which 3D8 scFv genes are cloned, were transfected into PT67 cells as packaging cell lines. 2×105 of the PT67 cells were grown on one well of 6-well plates for about 24 hours and washed with serum-free TOM™ (Welgene, Inc.). 2 □ of DNA, 5 □ of lipofectamine™ (Invitrogen, Corp.) and 200 □ of TOM™ were mixed with one another, allowed to react at ambient temperature for 15 min, 800 □ of a TOM™ medium were further added thereto, poured into the cell-containing wells and incubated in a 5% CO2 incubator at 37° C. for 8 hours. After 8 hours, the cells were cultured in a 10% fetal calf serum-containing DMEM medium for about 24 hours and the medium used was replaced with G418 800 □/ml-containing DMEM-10% fetal calf serum medium. After about two weeks, when the cells began to cluster and were grown in the wells, they were cultured for about 2 to 3 days and centrifuged to obtain a viral supernatant. The remaining solution was filtered through 0.45 um filter to remove cell residues.
To transduce 3D8 scFv gene-containing retrovirus particles obtained from PT67 packaging cell lines into HeLa and PK15 cells, 1×105 of HeLa cells and PK15 cells (porcine kidney fibroblast cell) were cultured on 60 mm culture plates for about 24 hours, and incubated in a 5% CO2 incubator using a 10% serum-containing DMEM medium supplemented with polyblene (10 □/ml) at 37° C. for two weeks. The cells were incubated in the medium supplemented with 5 mL of the viral supernatant obtained by culturing the PT67 packaging cells at 37° C. for 24 hours, and G418 selection was conducted using 1 mg/ml of a G418-containing medium.
At about three weeks after the transfection of the HeLa and PK15 cells with retrovirus, when clusters of the transduced cells were formed by the G418 selection, limiting dilution was performed such that 0.5 cells were introduced into one well of 96-well plates to establish monoclonal cell lines. H4-2, H5-14, H5-18 and H5-26 were established as representative HeLa cell lines transfected with the retrovirus and P1-1, P1-2 and P1-3 were established as representative PK cell lines transfected with the retrovirus.
As shown in
Antiviral activities of the NIH/3T3, and HeLa cell lines, in which 3D8 scFv genes were proven to be expressed, were ascertained. Specifically, the NIH/3T3 cell lines were evaluated for antiviral activity against vesicular stomatitis virus (VSV), the HeLa cell lines were evaluated for antiviral activity against VSV, herpes simplex virus (HSV) and Aujesky's disease virus (ADV), and the PK15 cell lines were evaluated for antiviral activity against classical swine fever virus (CSFV).
The amount of virus infected into the transformed cell lines was in a multiplication of infection (MOI) range of 0.1 to 1.0. To ascertain the antiviral activities of respective cell lines, the cell lines were infected with viruses, and after about 20-72 hours, cell death monitoring, RT-PCR or intracellular virus staining was performed. The antiviral activities of respective cell lines were ascertained in accordance with the following manner:
Ascertainment of antiviral activity against VSV (negative-strand RNA genome)
Observation of cell death with a microscope at 20-40 hours following the virus infection
Ascertainment of antiviral activity against HSV (double-strand DNA genome)
Observation of cell death with a microscope at 20-40 hours following virus infection
Observation of cell death with a microscope at 24 hours following the infection of the cells with HSV-GFP (green fluorescent protein) virus that fluoresces green when expresses GFP in cells.
Ascertainment of antiviral activity against ADV (double-strand DNA genome)
Performance of ADV gp50 gene-targeting RT-PCR at 40 hours following the infection.
Evaluation of antiviral activity against CSFV (positive-strand RNA genome)
Staining of intracellular virus at 72 hours following the infection.
At 24 hours following the infection of the cells with VSV at MOI 1, cell survival rates of the cell lines were compared with one another. Specifically, the survival rate of the non-transformed NIH/3T3 cell lines was about 47%, whereas survival rate of the 3D8 scFv gene-transformed NIH/3T3 cell lines was about 76%. Similarly, the survival rate of the non-transformed HeLa cells was about 32%, whereas the survival rate of 3D8 scFv-transformed HeLa cells was about 85% (
As can be seen from
Meanwhile,
At 24 and 36 hours following infection of the cells with VSV (at MOI=0.1 or 1), survival rates of the cell lines were compared with one another. As a result, it was confirmed that the survival rate of the 3D8 scFv gene-transformed H4-2 cells was higher than that of non-transformed HeLa cells, and in particular, survival rates of the 3D8 scFv gene-transformed H4-2 cells were about 75% at MOI 1 and about 88% at MOI 0.1 (
At 24 hours following the infection of the cells with HSV-GFP at MOI 1 and MOI 0.5, fluorescent activities of the cells were observed. From the observation, it was seen that fluorescing cell ratio of the transformed HeLa cells was lower than that of non-transformed HeLa cells. These results indicated that 3D8 scFv proteins are capable of inhibiting multiplication of VSV in HeLa cells.
The base sequence of primer used for the PCR is as follows. The primer targets gp50 genes of ADV virus.
As apparent from
In conclusion, the afore-mentioned results demonstrated multiplication of DNA virus (e.g., ADV and HSV) and RNA virus (e.g., VSV and CSFV) was inhibited in 3D8 scFv protein-expressing cells.
Formulation Example 1 Formulation of 3D8 scFv Proteins ScFv (SEQ ID NO: 6) 40 □Tween 802 mg
Glycine 2 g
A composition (20 mL) was prepared by dissolving the ingredients in an injection-purpose physiological saline, subjected to sterile-filtration, divided into 2-mL vials, lyophilized and then sealed.
Formulation Example 2 Formulation of 3D8 scFv Proteins ScFv (SEQ ID NO: 6) 40 □Tween 801 mg
Sorbitol 2g
Glycine 1 g
A composition (20 mL) was prepared by dissolving the ingredients in an injection-purpose physiological saline, subjected to sterile-filtration, divided into 2-mL vials, lyophilized and then sealed.
Formulation Example 3 Formulation of 3D8 scFv ProteinsScFv (SEQ ID NO: 6) 20 0
Serum albumin 501 mg
Sorbitol 4 g
A composition (20 mL) was prepared by dissolving the ingredients in a 0.01M phosphate buffer solution (PBS, pH 7.0), subjected to sterile-filtration, divided into 2-mL vials, lyophilized and then sealed.
Administration Example 1 Intramuscular Injection of 3D8 scFv DNA100□ of vector DNAs expressing ScFv proteins (SEQ ID NO: 6) were intramuscularly injected into quadricep muscles of mice. 50 □ of the vector DNAs diluted in 0.9% NaCl were each injected into both quadricep muscles of mice.
After the injection, electroporation was performed by placing an electrode on muscles adjacent to the site injected and applying an electrical potential having 10 trains of 1,000 pulses to the site. At this time, a length of the pulse applied was 200 □ (twice), an interval between two successive pulses was 600 □ and a current limit was 50 mA. A conductive gel was used for the skin. In the case of larger animals, the electrode may be inserted into muscles of the animals.
INDUSTRIAL APPLICABILITYAs apparent from the foregoing, the present invention can be applied to animal cells, in particular, to human cells, thus being widely utilized in the medication industry associated with the treatments for diseases derived from a variety of virus including HIV virus and SARS virus.
Claims
1. An antiviral agent against animal viruses, the antiviral agent containing, as an active ingredient, a protein that has binding and degrading abilities to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself.
2. An antiviral agent against animal viruses, the antiviral agent containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding and degrading abilities selective for foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself.
3. The antiviral agent against animal viruses according to claim 2, wherein the nucleic acid sequence is a DNA sequence.
4. The antiviral agent against animal viruses according to claim 3, wherein the DNA sequence is a nucleic acid sequence introduced into a vector capable of expressing genes in animal cells.
5. The antiviral agent against animal viruses according to claim 1, wherein the protein is obtained from an autoimmune disease-induced animal.
6. The antiviral agent against animal viruses according to claim 5, wherein the autoimmune disease is induced by malfunction of an Ipr gene.
7. The antiviral agent against animal viruses according to claim 5, wherein the autoimmune disease-induced animal is a mouse.
8. The antiviral agent against animal viruses according to claim 1, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to RNA chains, or binding and degrading abilities to DNA chains.
9. The antiviral agent against animal viruses according to claim 1, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to both RNA and DNA chains.
10. The antiviral agent against animal viruses according to claim 1, wherein the protein is immunoglobulin or a fragment thereof having binding and degrading abilities to foreign nucleic acid chains.
11. The antiviral agent against animal viruses according to claim 10, wherein the immunoglobulin is immunoglobulin G (IgG).
12. The antiviral agent against animal viruses according to claim 10, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, Fv and scFv, or any combination thereof.
13. The antiviral agent against animal viruses according to claim 11, wherein the IgG is 3D8.
14. The antiviral agent against animal viruses according to claim 12, wherein the scFv has a sequence as set forth in SEQ ID NO 6.
15. The antiviral agent against animal viruses according to claim 12, wherein the VH has a sequence as set forth in SEQ ID NO 2.
16. The antiviral agent against animal viruses according to claim 12, wherein the VL has a sequence as set forth in SEQ ID NO 4.
17. The antiviral agent against animal viruses according to claim 1, wherein the virus invaded in an animal cell is RNA virus.
18. The antiviral agent against animal viruses according to claim 17, wherein the RNA virus is acquired immunodeficiency syndrome (AIDS) virus or severe acute respiratory syndrome (SARS) virus.
19. An antiviral animal cell containing, as an active ingredient, a protein that has binding and degrading abilities to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself.
20. An antiviral animal cell containing, as an active ingredient, a nucleic acid sequence encoding a protein that has binding and degrading abilities to foreign nucleic acid chains invaded in an animal cell and has no cytotoxicity to the animal cell itself.
21. The antiviral animal cell according to claim 20, wherein the nucleic acid sequence is a DNA sequence.
22. The antiviral animal cell according to claim 21, wherein the DNA sequence is a nucleic acid sequence introduced into a vector capable of expressing genes in animal cells.
23. The antiviral animal cell according to claim 19, wherein the protein is obtained from an autoimmune disease-induced animal.
24. The antiviral animal cell according to claim 23, wherein the autoimmune disease is induced by malfunction of an Ipr gene.
25. The antiviral animal cell according to claim 23, wherein the autoimmune disease-induced animal is a mouse.
26. The antiviral animal cell according to claim 19, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to RNA chains, or binding and degrading abilities to DNA chains.
27. The antiviral animal cell according to claim 19, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to both RNA and DNA chains.
28. The antiviral animal cell according to claim 19, wherein the protein is immunoglobulin or a fragment thereof, having binding and degrading abilities to foreign nucleic acid chains.
29. The antiviral animal cell according to claim 28, wherein the immunoglobulin is immunoglobulin G (IgG).
30. The antiviral animal cell according to claim 28, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, Fv and scFv, or any combination thereof.
31. The antiviral animal cell according to claim 29, wherein the IgG is 3D8.
32. The antiviral animal cell according to claim 30, wherein the scFv has a sequence as set forth in SEQ ID NO 6.
33. The antiviral animal cell according to claim 30, wherein the VH has a sequence as set forth in SEQ ID NO 2.
34. The antiviral animal cell according to claim 30, wherein the VL has a sequence as set forth in SEQ ID NO 4.
35. The antiviral agent against animal viruses according to claim 2, wherein the protein is obtained from an autoimmune disease-induced animal.
36. The antiviral agent against animal viruses according to claim 35, wherein the autoimmune disease is induced by malfunction of an Ipr gene.
37. The antiviral agent against animal viruses according to claim 35, wherein the autoimmune disease-induced animal is a mouse.
38. The antiviral agent against animal viruses according to claim 2, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to RNA chains, or binding and degrading abilities to DNA chains.
39. The antiviral agent against animal viruses according to claim 2, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to both RNA and DNA chains.
40. The antiviral agent against animal viruses according to claim 2, wherein the protein is immunoglobulin or a fragment thereof having binding and degrading abilities to foreign nucleic acid chains.
41. The antiviral agent against animal viruses according to claim 40, wherein the immunoglobulin is immunoglobulin G (IgG).
42. The antiviral agent against animal viruses according to claim 40, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, Fv and scFv, or any combination thereof.
43. The antiviral agent against animal viruses according to claim 41, wherein the IgG is 3D8.
44. The antiviral agent against animal viruses according to claim 42, wherein the scFv has a sequence as set forth in SEQ ID NO 6.
45. The antiviral agent against animal viruses according to claim 42, wherein the VH has a sequence as set forth in SEQ ID NO 2.
46. The antiviral agent against animal viruses according to claim 42, wherein the VL has a sequence as set forth in SEQ ID NO 4.
47. The antiviral animal cell according to claim 20, wherein the protein is obtained from an autoimmune disease-induced animal.
48. The antiviral animal cell according to claim 47, wherein the autoimmune disease is induced by malfunction of an /pr gene.
49. The antiviral animal cell according to claim 47, wherein the autoimmune disease-induced animal is a mouse.
50. The antiviral animal cell according to claim 20, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to RNA chains, or binding and degrading abilities to DNA chains.
51. The antiviral animal cell according to claim 20, wherein the binding and degrading abilities to foreign nucleic acid chains are binding and degrading abilities to both RNA and DNA chains.
52. The antiviral animal cell according to claim 20, wherein the protein is immunoglobulin or a fragment thereof, having binding and degrading abilities to foreign nucleic acid chains.
53. The antiviral animal cell according to claim 52, wherein the immunoglobulin is immunoglobulin G (IgG).
54. The antiviral animal cell according to claim 52, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, Fv and scFv, or any combination thereof.
55. The antiviral animal cell according to claim 53, wherein the IgG is 3D8.
56. The antiviral animal cell according to claim 54, wherein the scFv has a sequence as set forth in SEQ ID NO 6.
57. The antiviral animal cell according to claim 54, wherein the VH has a sequence as set forth in SEQ ID NO 2.
58. The antiviral animal cell according to claim 54, wherein the VL has a sequence as set forth in SEQ ID NO 4.
59. The antiviral agent against animal viruses according to claim 10, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, or any combination thereof.
60. The antiviral animal cell according to claim 28, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, or any combination thereof.
61. The antiviral agent against animal viruses according to claim 40, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, or any combination thereof.
62. The antiviral animal cell according to claim 52, wherein the immunoglobulin fragment comprises one selected from the group consisting of VH, VL, or any combination thereof.
Type: Application
Filed: Sep 18, 2007
Publication Date: Aug 18, 2011
Applicants: Sungkyunkwan University Foundaton for Corporate Collaboration (Suwon-Si, Gyeonggi-Do), Ajou University Industry-Academic Cooperation Foundation (Gyeonggi-do), Invitroplant Co., Ltd. (Suwon-Si, Gyeonggi-Do)
Inventors: Suk-Chan Lee (Suwon), Yong-Sung Kim (Suwon), Myung-Hee Kwon (Suwon), Tai-Hyun Kim (Suwon), Jeong-Sun Kim (Gwangju), Gun-Sup Lee (Suwon), Hye-Kyung Shim (Suwon), Eul-Yong Park (Yongin), Yu-Chul Jung (Goyang), Ki-Yoon Kim (Jeonju), Yi-Jung Jung (Seoul), Woo-Ram Lee (Siheung), Young-Rim Kim (Seoul), Jong-Nam Sohn (Seoul), Seung-Hyun Lee (Wonju)
Application Number: 12/441,965
International Classification: C12N 5/00 (20060101); C07H 21/04 (20060101); C07K 16/10 (20060101);
